key: cord-0786455-1a664hr2 authors: Vandergaast, R.; Carey, T.; Suksanpaisan, L.; Lathrum, C.; Narjari, R.; Haselton, M.; Schnebeck, L.; Wijesekara, A.; Duncan, A.; Russell, L.; Naik, S.; Peng, K.-W.; Lech, P.; Russell, S. J. title: Longitudinal monitoring of SARS-CoV-2 neutralizing antibody titers and its impact on employee personal wellness decisions date: 2022-03-02 journal: nan DOI: 10.1101/2022.03.01.22271202 sha: ede0f47c3c676ee79eb060f8e732c8be3813a9c1 doc_id: 786455 cord_uid: 1a664hr2 Virus neutralizing antibody (vnAb) titers are the strongest laboratory correlate of protection from SARS-CoV-2. Providing individuals with real-time measures of their vnAb titers is predicted to improve their ability to make personal wellness decisions. Yet, widespread commercial testing of SARS-CoV-2 vnAbs does not currently occur. Here, we examined whether knowing their vnAb titer impacted wellness decision-making among individuals. To this end, starting on January 1, 2021, we offered all employees from two companies free IMMUNO-COV testing and conducted a survey to assess their behaviors and decisions regarding booster vaccination. IMMUNO-COV is a clinically validated, surrogate virus assay that quantitates serum titers of SARS-CoV-2 vnAbs. To help participants gauge their level of protection based on their vnAb titer, we calibrated IMMUNO-COV titers to the World Health Organization (WHO) International Standard (IU/mL), making them comparable to published reports of correlates of protection, and we fit historical IMMUNO-COV vnAb titer values into predictive models of immune protection from COVID-19. As expected, data for the 56 program participants showed variability in vnAb titers post vaccination, rates vnAb decay, and fold-increases in vnAb titers after booster vaccination. Based on the participant survey, the majority (66%) of participants indicated that knowing their vnAb titer impacted their social behaviors and/or their decision on the timing of a booster vaccination. Several participants indicated that knowing their vnAb titer contributed to their peace of mind regarding their high level of protection from COVID-19. Together, these data demonstrate that regular determination of SARS-CoV-2 neutralizing antibody titers can significantly impact decisions regarding social interactions and timing of booster vaccinations. Virus neutralizing antibody (vnAb) titers are the strongest laboratory correlate of protection from SARS-CoV-2. Providing individuals with real-time measures of their vnAb titers is predicted to improve their ability to make personal wellness decisions. Yet, widespread commercial testing of SARS-CoV-2 vnAbs does not currently occur. Here, we examined whether knowing their vnAb titer impacted wellness decision-making among individuals. To this end, starting on January 1, 2021, we offered all employees from two companies free IMMUNO-COV TM testing and conducted a survey to assess their behaviors and decisions regarding booster vaccination. IMMUNO-COV is a clinically validated, surrogate virus assay that quantitates serum titers of SARS-CoV-2 vnAbs. To help participants gauge their level of protection based on their vnAb titer, we calibrated IMMUNO-COV titers to the World Health Organization (WHO) International Standard (IU/mL), making them comparable to published reports of correlates of protection, and we fit historical IMMUNO-COV vnAb titer values into predictive models of immune protection from COVID-19. As expected, data for the 56 program participants showed variability in vnAb titers post vaccination, rates vnAb decay, and fold-increases in vnAb titers after booster vaccination. Based on the participant survey, the majority (66%) of participants indicated that knowing their vnAb titer impacted their social behaviors and/or their decision on the timing of a booster vaccination. Several participants indicated that knowing their vnAb titer contributed to their peace of mind regarding their high level of protection from COVID-19. Together, these data demonstrate that regular determination of SARS-CoV-2 neutralizing antibody titers can significantly impact decisions regarding social interactions and timing of booster vaccinations. In 2021, several key studies indicated that SARS-CoV-2 virus neutralizing antibody (vnAb) titers provide the best correlate of protection from future infection, correlating strongly with vaccine efficacy for both mRNA and adenovirus vaccines and providing the best predictor of individual risk of infection [1] [2] [3] [4] . Breakthrough infections, which occur most commonly with SARS-CoV-2 variants, coincide with low vnAb titers in individuals and with overall waning immunity in some vaccinated populations [5] [6] [7] . Therefore, when individuals know their vnAb titer, they can more accurately predict their level of protection from future SARS-CoV-2 infection. When considered in combination with their medical history, this information can help them more precisely evaluate the risks and benefits of their behaviors and medical decisions. Numerous serological assays for detecting SARS-CoV-2 antibodies have been developed. However, most are qualitative, do not look specifically for neutralizing antibodies, or are for research use only. Thus, patient access to vnAb testing is limited. IMMUNO-COV was developed as a collaboration between Vyriad, Inc., Regeneron Pharmaceuticals, and Imanis Life Sciences 8 . It is a clinically validated laboratory developed test (LDT) that measures SARS-CoV-2 vnAb titers in blood (serum or plasma) samples. Initially launched in April 2020, IMMUNO-COV was the first commercially scalable test of its kind, available to patients through physician order for accurate measure of an individual's vnAb titer. In early 2021, following the rollout of vaccination programs and the launch of IMMUNO-COV v2.0 9 , free testing was offered to all employees from two companies. This free testing provided employees the opportunity to measure their level of protection from COVID-19 in realtime following vaccination or recovery from infection, allowing them to personally assess the risks of their behaviors during the COVID-19 pandemic. During the period of this study, the dominant SARS-CoV-2 variant in the U.S.A. evolved from Wuhan (ancestral) to Delta (B.1.617.2). Here, we report on our retrospective study of individuals involved in the free IMMUNO-COV testing program. Of the employees that participated in the program from January 1 through December 4, 2021, we had data from 56 evaluable participants encompassing the time from first vaccination series through booster vaccination. To correlate IMMUNO-COV titers with published reports and help participants more easily estimate their level of protection from their test results, we calibrated the IMMUNO-COV assay to the World Health Organization (WHO) International Standard Unit (IU/mL) 10 . We also applied published models correlating vnAb titers and protection levels 1,2 to All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The study protocol, informed consent forms to collect blood, and participant survey were reviewed and approved by Western Institutional Review Board. Written informed consent was obtained from all study participants. We are reporting data collected from January 1 through December 4, 2021. IMMUNO-COV was offered free to all employees from two selected companies. Participants provided blood samples for IMMUNO-COV testing at intervals of their choosing before and after vaccination. Participants were notified of their personal test results 1-2 weeks after taking the test. Approximately 90% of employees participated in the study, all of whom received at least two doses of BNT162b2 vaccine (Pfizer-BioNTech) or mRNA-1273 vaccine (Moderna) or one dose of Ad26.CoV2.S (Janssen) during the study course. The study was performed retrospectively to characterize peak vnAb titers post vaccination and booster vaccination and examine the kinetics of vnAb decay. Data Collection: Participants completed a questionnaire that provided de-identified demographic information including age and gender, and information relevant to their COVID-19 immunity including date of first, second, and booster vaccination and the vaccine(s) that they received (see in part Table 1 ). Participants also informed us if they had COVID-19 prior to vaccination or a breakthrough infection following vaccination and provided the date of their COVID-19 test which detected SARS-CoV-2 by RT-PCR assay. Near the end of the study, participants were emailed a request to complete a survey, which was securely completed through DocuSign. Data Analysis and Statistics: Data was graphed and analyzed using Prism v9.3.1 (GraphPad Prism, San Diego, CA). Correlation analysis was performed with log-transformed data using Pearson's All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint correlation and simple linear regression with 95% confidence interval. Because the frequency of sample collection/testing varied between participants, with sample numbers ranging from one to ten per participant, we calculated mean average titers per two-month intervals and performed comparisons between each two-month interval. If a participant had two or more collection days in a time interval, only the highest vnAb titer was used. Collection days following booster vaccine or a breakthrough infection by SARS-CoV-2 were omitted for analyses of the kinetics of vnAb decay. This was a retrospective study with a sample size too small for statistical intergroup comparisons. Sample collection was not stratified; blood samples for testing were not collected at the same intervals relative to vaccination for all participants and the number of data collection points varied between individuals. Only 16/56 (29%) participants had titers measured within 8-30 days post second vaccination, meaning the peak titers recorded for many participants likely underestimate their true peak titer. All correlates for protection are based on vnAb levels, which provide the best correlate of protection from future infection 1,2 . However, cellular immunity also plays a role in protecting against SARS-CoV-2, and cellular immune responses were not examined as part of this study. IMMUNO-COV Assay: Quantitation of vnAb titers was performed using IMMUNO-COV v2.0 (referred to throughout this manuscript as IMMUNO-COV) 9 . The clinically validated test detects the presence of specific neutralizing antibodies capable of inhibiting a vesicular stomatitis virus (VSV)-based surrogate virus, VSV-SARS2-Fluc. Infection by VSV-SARS2-Fluc results in the expression of firefly luciferase within infected ACE2-expressing cells and total luminescence corresponds to the extent of infection by VSV-SARS2-Fluc. The relative neutralizing capacity All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint present in an unknown sample is inversely proportional to the luminescence and is derived by reference to a standard curve. For most of the study period, vnAb titers were reported as an IMMUNO-COV-specific virus neutralizing titer (VNT) that correlates closely to results produced by a traditional plaque reduction neutralization test (PRNT). Near the end of the study, IMMUNO-COV titers were standardized to the World Health Organization (WHO) International Standard unit (IU/mL) and data presented here were retrospectively converted to IU/mL, making them comparable to titers obtained using other standardized neutralization assays. 11 . The rescued virus was amplified in Vero-ACE2 cells 9 to generate large-scale stocks for use in the assay. For vnAb assay, test serum samples at increasing dilutions were incubated with VSV-SARS2(Delta)-Fluc (800 pfu/100 µL) for 30 min at room temperature, before being overlaid onto monolayers of Vero-ACE2 cells plated 16-24 h before use. After an additional 28 h, d-luciferin substrate was added to wells and bioluminescence was measured using a Tecan M Plex or Tecan Lume instrument (100 ms integration, 100 ms settle time per well). Pooled seronegative serum control was included on every assay plate and the relative luciferase signal (response) in wells for each sample dilution were normalized to the luciferase signal from the negative control wells. Percent response values were plotted against dilution factors and regression analyses were performed. A 50% inhibitory concentration (IC50) titer was determined from the fitted curves for each sample. For experiments comparing vnAb titers against SARS-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CoV-2 Wuhan and Delta, the original IMMUNO-COV v2.0 assay was run in a similar IC50 format, and IC50 titers were determined rather than typical IMMUNO-COV VNT or IU/mL titers. The negative reference sample was tested at 1:80 only, which is the starting dilution of the standard IMMUNO-COV assay. Each assay plate also included the IMMUNO-COV standard curve, consisting of stepped concentrations of neutralizing monoclonal antibody mAb10914, which was used to calculate the IMMUNO-COV VNT of each reference sample. A second neutralizing monoclonal antibody, mAb10922, was also used for comparisons. Percent luciferase responses normalized to a negative control of pooled seronegative serum (included on every assay plate) were determined for each dilution, and dilutions that resulted in a luciferase signals that fell within the dynamic range of the assay were used to perform parallelism analyses of the reference samples and monoclonal antibody controls. Regression analyses and curve fitting (4-parameter logistic) were performed using Prism. From these analyses, the Hill slope was confirmed to be the same (F value All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint = 1.433, p value = 0.2627). The neutralizing potency in IU/mL for each Reference Standard was provided ( Table 2 ) and plotted against the corresponding mean geometric VNT titer results (from dilutions within the linear range) from the IMMUNO-COV assay for regression analyses. Several regression models were considered, but for the ease of performing data conversion, a linear regression with no intercept model was chosen (r 2 = 0.9080). Based on this analysis, the correction factor for conversion of VNT values to WHO IU/mL values was 0.6954. The predictive models utilized in this study were based on data and algorithms provided in the primary source publications and were obtained from the GitHub repository associated with each primary source. 1, 2 The source models were generated to evaluate protection based on the mean neutralization level as a fold-change of convalescent neutralization levels. Therefore, the adaptation of these models to evaluate protection of SARS-CoV-2, both ancestral (wildtype) and Delta based on IMMUNO-COV titers, required obtaining the mean convalescent titer from ancestral virus. Data collected early in the launch of the assay, prior to vaccines becoming readily available, was analyzed and although the specific details as to the timing of convalescence was not known in all cases, a mean convalescent titer was calculated from the geometric mean of 264 convalescent samples. The geometric mean of convalescent titers measured by the IMMUNO-COV, which was applied to the predictive models was 325.6 IU/mL (95% CI: 289.7 to 366 IU/mL). Transforming the fold-change of mean convalescent to this measured value from the IMMUNO-COV datasets yielded the models of protection established in this report and were also applied to Delta protection model according to similar assumptions set in the source models of protection. Prior reporting for models of protection using WHO IU/mL values is still limited at the time of publication, but Khourey et al. reported that 50% protection against All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint symptomatic disease from SARS-CoV-2 Wuhan infection corresponds to 54 IU/mL 1 . Using the IMMUNO-COV predictive models, a similar titer result of 67 IU/mL was calculated to yield 50% protection against SARS-CoV-2 Wuhan infection. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A total of 214 serum samples were collected from 56 participants post primary vaccination against SARS-CoV-2 (Table 1) (Table 1) . During the study period, 37/56 (66%) participants received a booster vaccine, of which 24/56 (43%) had pre-and post-booster vaccine samples collected. Booster doses were BNT162b2 (32/37), mRNA-1273 (3/37), or Ad26.CoV.S (2/37), and were received as early as five months post primary vaccination. Four participants (7%) tested positive for COVID-19 prior to the start of the study and receipt of their primary vaccine, while two participants (4%) had break-through infections following vaccination. To readily compare IMMUNO-COV vnAb titers from this study with other published reports of correlates of protection, we calibrated IMMUNO-COV titers to the World Health All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Organization International Standard unit (IU/mL) 10 . To this end, we ran samples from the First WHO International Reference Panel for anti-SARS-CoV-2 Immunoglobulin (NIBSC code 20/268) and the SARS-CoV-2 National Standard (FNL) in multiple analytical runs on the IMMUNO-COV assay. Together, these reference samples include one negative sample and five positive samples ranging from low to moderately high titer ( Table 2) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint SARS-CoV-2 surrogate virus neutralization assay (GenScript) 12 had lower sensitivity and poor quantitation when used to measure the Reference Samples (Table 2 ). This data further emphasizes the accuracy of the functional IMMUNO-COV assay relative to a neutralization assay that relies on binding alone to measure vnAb titers. To help participants interpret vnAb titer results, we applied a predictive model of immune (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint at each dilution relative to negative control serum were used to determine a 50% inhibitory concentration (IC50). To facilitate comparisons with Wuhan neutralization, for this assessment, the IMMUNO-COV assay was also run using dilution series to calculate IC50 titers. Three seropositive samples from previously vaccinated, non-convalescent participants were tested sideby-side in the Wuhan and Delta assays. For each sample, the luciferase response curves for Wuhan were clearly shifted toward higher dilutions (higher IC50 values) compared to luciferase response curves for Delta (Figure 2A) . The degree of this shift ranged from 2.2 to 3.4-fold. Overall, the consensus curves demonstrated a shift of 2.76-fold ( Figure 2B ), indicating that vaccine-elicited vnAbs demonstrate an in vitro neutralizing potency that is 2.76-fold higher against SARS-CoV-2 Wuhan compared to Delta variant. This in vitro relative potency, is lower than the 3.9 considered in the published model of protection 2 , which is likely due to either differences between in vitro neutralization levels and protection levels, or to the small sample size used in our testing that may not represent the full range of variation seen between individuals. Using internally collected historical data from IMMUNO-COV, we estimated the IMMUNO-COV vnAb titer needed for 50% protection against mild infection to be 67 IU/mL for SARS-CoV-2 Wuhan and 269 IU/mL for SARS-CoV-2 Delta ( Figure 3A & C) . Furthermore, we estimated the IMMUNO-COV vnAb titer needed for 50% protection against severe disease to be 10 IU/mL for Wuhan and 39 IU/mL for Delta ( Figure 3B & D) . The IMMUNO-COV limit of detection is 22 IU/mL. Thus, any detectable level of vnAbs likely confers some level of protection against severe disease, particularly in healthy individuals where cell-mediated adaptive immunity also helps reduce sickness from breakthrough infections. Of note, protection levels represent the degree that an individual's baseline risk is reduced and do not account for underlying risk factors that an individual may already have from comorbidities. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Peak vnAb titers were significantly higher following booster vaccination compared to primary vaccination. Modest increases in vnAb titers not attributable to breakthrough infection or booster vaccination were observed in 14/52 (27%) participants, primarily during the first SARS-CoV-2 Delta surge. Thus, these increases may have resulted from exposure or asymptomatic infections that were not recognized by participants, though variability in sample handling, or runto-run assay variability may have also contributed to modest titer increases. Several studies have reported that SARS-CoV-2 vnAb titers in convalescent individuals [13] [14] [15] and vaccinees 16, 17 show rapid early decay that slows over time. This trend is consistent with a burst of short-lived antibody secreting cells producing peak vnAb titers, which decay rapidly until reaching a slowly declining plateau maintained for months to years by long-lived memory B cells. In our study, vnAb titers displayed similar kinetics, with titers in over half (32/52; 62%) of the participants reaching apparent homeostasis as early as three months post primary vaccination ( Figure 4) . When the kinetics of vnAb decay were analyzed in 60-day intervals (Figure 5 ), the All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. half-life of vnAb decay averaged 1.77 months from the first two months to four months following vaccination. Because only 16/56 (29%) participants had titers measured within 8-30 days post second vaccination, peak titers were likely underestimated for many participants, and therefore, the rate of decay from two to four months is likely also underestimated. From four to six months following vaccination, the half-life of vnAb decay was 2.17 months, which dropped to 1.60 months from six to eight months post vaccination. This reduction in mean half-life was attributed in largepart to the 62% of participants that reached vnAb homeostasis, as the half-life for individuals who had not yet reached homeostasis was much higher (2.43 months compared to 1.08 months for individuals reaching homeostasis). Interestingly, individuals that reached homeostasis within six months, were primarily those with higher peak titers following vaccination. Comparison of the rate of decay between the three vaccine platforms was not performed due to insufficient longitudinal collections from mRNA-1273 and Ad26.CoV.S vaccinees. A moderate negative correlation of statistical significance between vnAb levels and age was observed (Pearson's coefficient, R -0.3552, P-value 0.0025) ( Figure 6 ). When the correlation between age and vnAb levels was calculated per 60-day intervals, the negative correlation was more dramatic at later time points (Table 3 ), suggesting that the rate of vnAb decay increases with age. Consistent with this observation, the mean age of participants that maintained vnAb titers above 200 IU/mL over the course of the study (mean age 36 yrs, range 22-64 yrs) was lower than the mean age of participants whose vnAb dropped below 200 IU/mL (mean 44 yrs, range 24-64). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Booster vaccinations were received by 37 (66%) participants. For 24 of the participants, vnAb titers were measured pre-boost and post-boost, and booster vaccination was associated with a mean 60.2-fold (range: 4.7 -336.6) increase in vnAb titer (Figure 4 and Table 4 ). In 23/24 (96%) participants, boosted vnAb titers peaked above 900 IU/mL, corresponding to a predicted level of over 75% protection from infection and over 90% protection from severe disease caused by SARS-CoV-2 Delta. However, vnAb titers were transient and began to decay shortly after reaching peak levels ( Figure 4 ). Two participants (3.6%), whose vnAb titers had dropped to 32 IU/mL and 27 IU/mL post primary vaccination, experienced breakthrough SARS-CoV-2 infections during the first Delta surge (Figure 4 , orange lines). The breakthrough infections also provided an effective boost in vnAb titer that was comparable to the boost in titer observed following booster vaccination. To evaluate how real-time knowledge of vnAb titers impacted individual's behavior and personal health decisions, a survey was sent to study participants at the end of 2021. A total of 44 (79%) participants returned results for the survey. Most participants (82%) considered knowing their individual vnAb titer as a positive experience ( Figure 7A ). The two individuals who had a negative impression of knowing their vnAb titer, indicated the information was useful, but disappointing due to their waning titer over time. The majority of participants (66%) also indicated that knowing their vnAb titer had a moderate to significant impact on their social behaviors ( Figure 7B ), including their practice of mask wearing in high-risk areas or activities and their participation in travel or family/social gatherings. Importantly, 66% of participants indicated that knowing their All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint vnAb titer impacted their decision on when or if to get a booster vaccine ( Figure 7C ). Approximately, 23% of participants reported that they would like to repeat the test every six months, whereas the majority (75%), preferred a more frequent testing schedule ( Figure 7D ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint Starting from January 1, 2021, employees from two companies were offered free access to IMMUNO-COV testing for determination of their vnAb titers against SARS-CoV-2. The goal of offering free testing was to provide a unique opportunity for participants to monitor their response to vaccination or natural infection, track their vnAb titers, and estimate their level of protection from future infection or disease in real time. The results of this study underscore the variability in vnAb titers and rates of decay among vaccinated individuals and highlight the need for frequent vnAb testing in personalized health assessments and behavioral decision making. Indeed, most study participants considered the knowledge of personal antibody titers to be helpful and used their vnAb titers to guide decisions regarding social gatherings and timing of booster vaccination. Throughout the study year (2021), there were numerous local and federal recommendations and/or mandates addressing matters such as masking, social distancing, quarantining and vaccination. Individuals were specifically discouraged from using antibody testing to determine their own immune status and from making personalized decisions on that basis. Notably, the FDA issued a strongly worded recommendation in May 2021, discouraging the use of antibody testing as a means to determine the adequacy of a person's immune response to vaccination and as a measure of their protections from reinfection 18 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint Unfortunately, most clinically approved antibody tests lack the ability to measure vnAbs, the antibody class that has been shown to correlate with protection. Instead, they detectoften qualitativelyantibodies capable of binding to the SARS-CoV-2 spike glycoprotein or nucleocapsid [19] [20] [21] . Because many binding antibodies are incapable of preventing virus infection, the information provided by such tests can be informative, but does not correlate as strongly to levels of protection as vnAb titers. IMMUNO-COV is a functional assay that uses a surrogate virus to specifically quantitate the titer of antibodies capable of preventing SARS-CoV-2 infection of cells. Thus, IMMUNO-COV titers provide a much better correlate of protection than other commercial antibody tests. Studies have used a variety of assays to measure vnAb titers, including plaque reduction neutralization test (PRNT) with clinical isolates of SARS-CoV-2, pseudo-typed lentiviral assays, and pseudovirus VSV assays. These assays have used different approaches to quantitate vnAb levels. To facilitate cross comparisons from studies, publications have increasingly reported vnAb titers in IU/mL, based on calibration of the assays to the WHO International Standard 10 . On this basis, we calibrated IMMUNO-COV titers (VNT) to the WHO International Standard ( Figure 1 and Table 2 ) and report here, our vnAb titer data in IU/mL. Due to availability of the WHO Reference Panel, calibration activities were not performed until fall 2021, and therefore, participants primarily received vnAb titer results in VNT units for this study. While vnAb titers provide a good correlate of protection from early infection, we received informal feedback throughout our study that some participants had difficulty interpreting their vnAb titer results. Similar feedback was also received from some patients who ordered IMMUNO-COV testing through their physicians. To address this concern and provide individuals with a resource for understanding how their vnAb titer relates to estimated protection, we applied All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint historical IMMUNO-COV titers from convalescent individuals to models of protection reported by Khoury et al. 1 CoV-2 Wuhan, and therefore, the initial modeling was done to correlate vnAb titer to protection from Wuhan (Figure 3 ). Because vnAbs demonstrate varying degrees of cross protection from SAR-CoV-2 viral variants, models of protection must be adjusted for each viral variant 2 . We also modeled IMMUNO-COV vnAb titer correlations with protections from SARS-CoV-2 Delta, which became the dominant strain within the U.S.A. during the course of this study. Models for SARS-CoV-2 Delta were based on a published conversion factor of 3.9 2 , which was similar to the relative potency factor of 2.76 that we calculated from a small sample set run side-by-side in IMMUNO-COV and IMMUNO-COV (Delta) assays ( Figure 2 ). Thus, for SARS-CoV-2 Delta, higher vnAb titers are required to provide protection when compared to Wuhan. While not directly modeled here, available scientific evidence [22] [23] [24] [25] [26] indicates that similar models of protection from the now dominant Omicron variant will be shifted even higher. In the current study, all participants developed neutralizing antibodies post vaccination after receiving BNT162b2, mRNA-1273, or Ad26.CoV.S vaccines (100% seroconversion rate). Over half (62%) of participants appeared to reach a state of vnAb homeostasis over six months post second vaccine dose ( Figure 4) . Additionally, in 56% of participants, vnAb titers remained above 200 IU/mL, representing an estimated 75% protection against infection from SARS-CoV-2 Wuhan (Figure 3 ). Consistent with previous reports, 17, 27, 28 we observed a negative correlation between vnAb titers and age ( Figure 6 ). Older participants on average were less likely to maintain titers above 200 IU/mL and demonstrated more rapid rates of vnAb decay. Most participants who received booster vaccines were previously vaccinated with BNT162b2 and received a homologous booster vaccine (Table 1) . All individuals experienced an increase in vnAb titers after booster All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint vaccination ( Figure 4) . Interestingly, individuals with pre-boost titers below 200 IU/mL demonstrated slightly larger fold increases in vnAb titers following booster vaccination but lower on average post-boost peak titers relative to individuals with pre-boost titers above 200 IU/mL (Table 4) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 2, 2022. ; https://doi.org/10.1101/2022.03.01.22271202 doi: medRxiv preprint Positive 85.4 †Value from runs in which sample tested positive. *According to cPass kit instructions, samples with an inhibition factor above 30 are considered positive. ND = not done All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science (80-. ) Covid-19 Breakthrough Infections in Vaccinated Health Care Workers New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight U.S. Locations Development and validation of IMMUNO-COV TM : a highthroughput clinical assay for detecting antibodies that neutralize SARS-CoV-2. bioRxiv IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community Neuroattenuation of Vesicular Stomatitis Virus through Picornaviral Internal Ribosome Entry Sites A SARS-CoV-2 surrogate virus neutralization test based on antibodymediated blockage of ACE2-spike protein-protein interaction Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination : FDA Safety Communication SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup Evaluation and Comparison of Serological Methods for COVID-19 Antibody detection assays for COVID-19 diagnosis: an early overview mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Article SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine *Data from 24 participants who gave blood samples pre-and post-vaccine boost We would like to thank the employees who participated in this testing